The CIS-treated group (p ≤ 0.001) and the EQ + CIS-treated group (p ≤ 0.0001) showed a significant downregulation of Bcl-2 gene expression as compared to the EQ-treated group (Figure 4E). The gene discussed is BCL2; the disease is in situ carcinoma.